PGNAA of human arthritic synovium for boron neutron capture synovectomy
- Massashucetts Institute of Technology, Cambridge, MA (United States)
- Brigham and Women`s Hospital, Boston, MA (United States)
Boron neutron capture synovectomy (BNCS), is a proposed new therapy modality for the treatment of rheumatoid arthritis, an autoimmune disease afflicting the joints. The synovium, which is the membrane lining the joint, becomes inflamed and represents the target tissue for therapy. When a joint is unresponsive to drug treatment, physical removal of the synovium, termed synovectomy, becomes necessary. Existing options include surgery and radiation synovectomy. BNCS has advantages over these options in that it is noninvasive and does not require the administration of radioactive substances. Previous studies have shown that the uptake of {sup 10}B by human arthritic synovium ex vivo is high, ranging from 194 to 545 ppm with an unenriched boron compound. While tissue samples remain viable up to 1 week, ex vivo conditions do not accurately reflect those in vivo. This paper presents results from experiments assessing the washout of boron from the tissue and examines the implications for in vivo studies.
- OSTI ID:
- 552709
- Report Number(s):
- CONF-971125-; ISSN 0003-018X; TRN: 98:001914
- Journal Information:
- Transactions of the American Nuclear Society, Vol. 77; Conference: 1997 American Nuclear Society (ANS) winter meeting, Albuquerque, NM (United States), 16-20 Nov 1997; Other Information: PBD: 1997
- Country of Publication:
- United States
- Language:
- English
Similar Records
In Vivo Boron Uptake Determination for Boron Neutron Capture Synovectomy
Final Technical Report